TheraRadar
Data updated: May 26, 2026

CONJUPRI (levamlodipine maleate)

Cardiovascular Approved 2019-12-19
Jump to: Indications Approvals Trials Competitors Safety Patents
1
Indication
--
Phase 3 Trials
6
Years on Market

Details

Status
Discontinued
First Approved
2019-12-19
Routes
ORAL
Dosage Forms
TABLET

Companies

CSPC OUYI
Active Ingredient: LEVAMLODIPINE MALEATE

CONJUPRI Approval History

2020
2021
2022
2023
2024
2025
2026
Original
New Indication
New Form
Label Update
3 FDA actions from 2019 to 2019
Dec 2019 ORIGINAL
Update · Type 2 - New Active Ingredient and Type 3 - New Dosage Form
FDA Letter Label

What CONJUPRI Treats

1 FDA approvals

Originally approved for its first indication in 2019 .

  • Other (1)
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...
⭐

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

ClinicalTrials.gov ↗ Pro

Full development history with FDA approval milestones

|
Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

CONJUPRI FDA Label Details

Track CONJUPRI with TheraRadar Pro

Watchlist alerts, full database access, CSV exports across 14,000+ drugs.

Upgrade to Pro

Data Sources

FDA Approval: NDA212895 → Patents: FDA Orange Book → Trials: ClinicalTrials.gov →

Data sourced from official FDA and NIH databases. Click links to verify on original sources.